Grant and Funding Programs Offered by The Michael J. Fox Foundation for Parkinson's Research (MJFF)

The Michael J. Fox Foundation for Parkinson's Research (MJFF) is a leading philanthropic funder focused exclusively on Parkinson’s disease and related parkinsonisms. Its stated goal is to “put itself out of business” by enabling scientific solutions that materially improve patients’ lives and ultimately deliver a cure. Since its inception, MJFF has funded over $1 billion in research programs and, by 2026, more than $2.5 billion in research initiatives overall.

Working with an in-house team of PhD neuroscientists and business strategists, MJFF runs peer-reviewed and staff-directed funding programs that evaluate more than 1,500 proposals per year. Around 30% of its research funding supports teams outside the United States, making MJFF a global funder of basic, translational and clinical research. The Foundation emphasizes rapid deployment of donor capital, holding no endowment and typically allocating funds within months of being raised.

MJFF supports a broad portfolio of grants and awards spanning discovery biology, biomarker development, drug development and care-related research. Competitive programs include the Edmond J. Safra Core Programs for PD Research, regular therapeutic pipeline calls and targeted initiatives such as the Targets to Therapies Program and the Therapeutics Pipeline Program. Publicly reported funding rounds describe hundreds of individual grants worth tens to hundreds of millions of dollars each year, awarded to academia, biotech and pharmaceutical partners worldwide.

In parallel, the Foundation spearheads landmark initiatives such as the Parkinson’s Progression Markers Initiative (PPMI), Fox Insight, Fox Trial Finder, digital health data-collection projects and training programs for the next generation of movement disorder specialists. Many of these efforts blend direct MJFF funding with co-funding from partner foundations, governments and industry.

Beyond traditional grants, MJFF runs or sponsors several high-impact prizes and challenge programs. These include the Bachmann-Strauss Prize for Excellence in Dystonia Research, which carries an unrestricted research grant, the Robert A. Pritzker Prize for Leadership in Parkinson’s Research, the $2-million Alpha-Synuclein Imaging Prize, and recurring data challenges that reward teams for extracting new insights from shared datasets. The Foundation also supports fellowships in movement disorders, dystonia research and related areas to grow clinical and scientific capacity.

Across its funding mechanisms, MJFF prioritizes projects with clear patient relevance and strong scientific rationale. Proposals are assessed through rigorous peer review and internal expert input, with milestone-driven project plans that enable course-correction and early termination when necessary. High-risk, high-reward science is actively encouraged, including work that other funders may consider too early or uncertain, as long as it can meaningfully de-risk therapeutic approaches or provide critical tools for the field.

A defining feature of MJFF’s model is its emphasis on open science and collaboration. Funded projects are expected to share tools, data and findings broadly and quickly with qualified researchers. The Foundation builds and leads consortia, imaging collaborations and research tools initiatives to align priorities and reduce duplication of effort. Impact is tracked not only through scientific outputs and biomarker or tool development, but also through follow-on investment from venture capital, industry and government and the progression of candidate therapies into and through clinical trials.